In the last trading session, 6,773,682 TherapeuticsMD, Inc. (NASDAQ:TXMD) shares changed hands as the company’s beta touched 1.99. With the company’s per share price at $1.33 changed hands at -$0.05 or -0.04% during last session, the market valuation stood at $515.81 Million. TXMD’s last price was a discount, traded about -106.77% off its 52-week high of $2.75. The share price had its 52-week low at $0.85, which suggests the last value was 36.09% up since then. When we look at TherapeuticsMD, Inc.’s average trading volume, we note the 10-day average is 7.7 Million shares, with the 3-month average coming to 15.25 Million.
Analysts gave the TherapeuticsMD, Inc. (TXMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 5 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended TXMD as a Hold, 5 felt it is a Buy and none rated the stock as Underweight. TherapeuticsMD, Inc.’s EPS for the current quarter is expected to be -$0.1.
Although TXMD has turned red as seen at the end of in last trading. With action -3.62%, the performance over the past five days has been red. The jump to weekly highs of $1.54 on Tuesday, Mar 23 added 13.64% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.1%, with the 5-day performance at -0.13% in the red. However, in the 30-day time frame, TherapeuticsMD, Inc. (NASDAQ:TXMD) is -0.13% down. Looking at the short shares, we see there were 57.57 Million shares sold at short interest cover period of 3.78 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.4, meaning bulls need an upside of 306.02% from its current market value. According to analyst projections, TXMD’s forecast low is $3 with $9 as the target high. To hit the forecast high, the stock’s price needs a +576.69% upsurge from its current level, while the stock would need to tank 125.56% for it to hit the projected low.
TherapeuticsMD, Inc. (TXMD) estimates and forecasts
Data shows that the TherapeuticsMD, Inc. share is not performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -5.67% over the past 6 months, a -44.44% in annual growth rate that is considerably lower than the industry average of 18.9%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for TherapeuticsMD, Inc. will rise +52.4%, while the growth in revenue is estimated to hit 52.6% for the next quarter. Year-over-year growth is forecast to reach 68.4% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $20.31 Million. 3 analysts are of the opinion that TherapeuticsMD, Inc.’s revenue for the quarter ending June 01, 2021 will be $24Million. The company’s revenue for the corresponding quarter a year ago was $12.25 Million. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 65.8%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -6.3%. The 2021 estimates are for TherapeuticsMD, Inc. earnings to increase by 6.9%, but the outlook for the next 5-year period is at 17.6% per year.
Even if you’re not actively in crypto, you deserve to know what’s actually going on…
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
TherapeuticsMD, Inc. (NASDAQ:TXMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.21% of TherapeuticsMD, Inc. shares while 54.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 60.88%. There are 194 institutions holding the TherapeuticsMD, Inc. stock share, with Blackrock Inc. the top institutional holder. As of Dec 30, 2020, the company held 5.52% of the shares, roughly 21.42 Million TXMD shares worth $25.92 Million.
Price (T.Rowe) Associates Inc holds the second largest percentage of outstanding shares, with 4.87% or 18.87 Million shares worth $22.83 Million as of Dec 30, 2020.
Among Mutual Funds, the top two as of Dec 30, 2020 were Price (T.Rowe) Small Cap Stock Fund and Fidelity Series Large Cap Stock Fund. With 9011312 shares estimated at $10.9 Million under it, the former controlled 2.32% of total outstanding shares. On the other hand, Fidelity Series Large Cap Stock Fund held about 2.11% of the shares, roughly 8.19 Million shares worth around $13.51 Million.